|1.||Eriksson, Ulf: 14 articles (08/2015 - 04/2002)|
|2.||Li, Xuri: 11 articles (10/2014 - 04/2002)|
|3.||Floege, Jürgen: 8 articles (08/2015 - 04/2002)|
|4.||Ostendorf, Tammo: 7 articles (08/2015 - 04/2002)|
|5.||Eitner, Frank: 7 articles (08/2015 - 04/2002)|
|6.||Fredriksson, Linda: 7 articles (01/2015 - 10/2004)|
|7.||Campbell, Jean S: 6 articles (09/2015 - 03/2005)|
|8.||Tang, Zhongshu: 6 articles (10/2014 - 04/2010)|
|9.||Fausto, Nelson: 5 articles (02/2014 - 03/2005)|
|10.||Gilbertson, Debra G: 5 articles (02/2014 - 10/2003)|
02/15/2014 - "PDGF-C transgenic mice provide a unique model for the in vivo study of tumor-stromal interactions in the liver. "
02/28/2014 - "Collectively, our results suggest that tumor cell-derived PDGF-C enhances TAM survival, promoting tumor malignancy. "
01/01/2014 - "Here, we show that PDGF-C is overexpressed in clinical breast cancers and correlates with poor prognosis. "
04/01/2013 - "By immunohistochemistry, PDGF-CC, PDGF-DD, and PDGFRα were found in tumor cells, whereas PDGFRβ was primarily detected in vascular stroma. "
09/01/2012 - "Ablation of PDGF-C in FIH-overexpressing tumor cells reduced pericyte coverage and tumor growth. "
03/01/2005 - "Moreover, PDGF-C transgenic mice represent a unique model for the study of hepatic fibrosis progressing to tumorigenesis."
03/01/2005 - "These studies indicate that hepatic expression of PDGF-C induces a number of profibrotic pathways, suggesting that this growth factor may act as an initiator of fibrosis. "
08/01/2015 - "From a clinical perspective, the profibrotic effects of PDGF-CC outweigh the pro-angiogenic effects and, thus, do not limit a potential therapeutic use of PDGF-CC inhibition in renal fibrosis. "
08/01/2015 - "PDGF-CC neutralization or deficiency was not associated with preservation or accelerated loss of peritubular capillaries, suggesting no significant pro-angiogenic effects of PDGF-CC during renal fibrosis. "
08/01/2015 - "Independent of the effect of PDGF-CC neutralization on renal fibrosis, we found no difference in capillary rarefaction between PDGF-CC-neutralized mice and mice with intact PDGF-CC. "
05/01/2014 - "Blood flow recovery and neovascularization after ischemia were significantly improved in the groups treated with PDGF-C compared with controls. "
05/01/2014 - "Mice deficient in PDGF-C exhibited reduced blood flow recovery after ischemia compared with wild-type mice, confirming a strong proangiogenic activity of PDGF-C. "
07/01/2008 - "Intraventricular injection of tPA or active PDGF-CC, in the absence of ischemia, leads to significant increases in cerebrovascular permeability. "
05/01/2014 - "Expression levels of PDGF-C at baseline and after ischemia were significantly lower in limb tissues of diabetic mice than in those of control mice, whereas expression levels of other members of the PDGF family and VEGF were not changed or were even higher in diabetic mice. "
04/12/2010 - "In several different animal models of neuronal injury, such as axotomy-induced neuronal death, neurotoxin-induced neuronal injury, 6-hydroxydopamine-induced Parkinson's dopaminergic neuronal death, and ischemia-induced stroke, PDGF-CC protein or gene delivery protected different types of neurons from apoptosis in both the retina and brain. "
06/01/2014 - "The protective effects of PDGF-C suggest a novel alternative approach for potential age-related retinal degeneration treatment. "
10/14/2014 - "Vasoprotective effect of PDGF-CC mediated by HMOX1 rescues retinal degeneration."
06/01/2014 - "We studied the possible survival and antiapoptotic effects of PDGF-C on focal retinal lesions in Ccl2(-/-)/Cx3cr1(-/-) on C57BL/6N [Crb1(rd8)] (DKO rd8) background mice, a model for progressive and focal retinal degeneration. "
06/01/2014 - "Platelet-derived growth factor (PDGF)-C inhibits neuroretinal apoptosis in a murine model of focal retinal degeneration."
|5.||Liver Cirrhosis (Hepatic Cirrhosis)
02/01/2014 - "PDGF-C Tg mice lacking tPA have high serum levels of cleaved growth factor, significant liver fibrosis, and gene expression alterations similar to those of PDGF-C Tg mice with intact tPA. "
02/01/2014 - "We developed mice that over-express full-length human PDGF-C in the liver; these mice develop progressive liver fibrosis. "
01/01/2013 - "PDGF-C antagonism, therefore, may not be effective to treat liver fibrosis."
01/01/2013 - "In contrast, in liver fibrosis there was either no difference (PDGF-C(-/-) mice) or even an upregulation of PDGFR-β and signaling (anti-PDGF-C group). "
11/01/2007 - "Specifically, overexpression of PDGF-C results in liver fibrosis, which is preceded by activation and proliferation of hepatic stellate cells, and is followed by the development of dysplastic lesions and angiogenesis, and progression to HCCs by 8 months of age. "
|1.||platelet-derived growth factor C (PDGF-C)
|2.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|3.||platelet-derived growth factor A
|4.||Human Immunodeficiency Virus rev Gene Products
|5.||Vascular Endothelial Growth Factor Receptor-3 (Flt 4)
|6.||Collagen Type I (Type I Collagen)
|8.||Peptide Hydrolases (Proteases)
|10.||Platelet-Derived Growth Factor